doxylamine has been researched along with Complications, Pregnancy in 54 studies
Doxylamine: Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in PARKINSONISM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report information about an unpublished 1970s study ("8-way" Bendectin Study) that aimed to evaluate the relative therapeutic efficacy of doxylamine, pyridoxine, and dicyclomine in the management of nausea and vomiting during pregnancy." | 9.24 | 8-Way Randomized Controlled Trial of Doxylamine, Pyridoxine and Dicyclomine for Nausea and Vomiting during Pregnancy: Restoration of Unpublished Information. ( Persaud, N; Zhang, R, 2017) |
| "Doxylamine succinate-pyridoxine hydrochloride delayed release combination is safe and well tolerated by pregnant women when used in the recommended dose of up to 4 tablets daily in treating nausea and vomiting of pregnancy." | 9.20 | Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial. ( Caritis, SN; Clark, S; Hankins, GD; Koren, G; Matok, I; Mattison, DR; Miodovnik, M; Umans, JG, 2015) |
| " The authors' objective is to identify the determinants of adherence to delayed-release doxylamine-pyridoxine (Diclectin) in patients with nausea and vomiting of pregnancy (NVP)." | 9.16 | Determinants of adherence to delayed-release doxylamine and pyridoxine in patients with nausea and vomiting of pregnancy. ( Caritis, S; Chiossi, G; Clark, S; Costantine, MM; Hankins, GD; Koren, G; Matok, I; Miodovnik, M; Umans, JG, 2012) |
| "To evaluate the effectiveness of Diclectin (doxylamine succinate 10 mg-pyridoxine hydrochloride 10 mg, delayed-release preparation) as compared with placebo for nausea and vomiting of pregnancy." | 9.14 | Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. ( Caritis, SN; Clark, S; Hankins, GD; Koren, G; Mattison, DR; Miodovnik, M; Umans, JG, 2010) |
| "Diclectin (pyridoxine 10 mg and doxylamine 10 mg) has traditionally been used to treat nausea and vomiting of pregnancy (NVP); however, this drug is unavailable in many countries." | 7.79 | Evaluation of the efficacy and safety of bi-daily combination therapy with pyridoxine and doxylamine for nausea and vomiting of pregnancy. ( Ashkenazi-Hoffnung, L; Klinger, G; Merlob, P; Stahl, B, 2013) |
| "A delayed-release combination of doxylamine-pyridoxine (D-P) (Diclectin) is the only approved antiemetic medication for use in pregnancy in Canada." | 7.71 | The safety of higher than standard dose of doxylamine-pyridoxine (Diclectin) for nausea and vomiting of pregnancy. ( Atanackovic, G; Koren, G; Moretti, ME; Navioz, Y, 2001) |
| " The pregnancy was complicated by chronic maternal schizophrenia, severe toxaemia and maternal use of fluphenazine enanthate, dicyclomine hydrochloride, doxylamine succinate, pyridoxine hydrochloride and other drugs." | 7.66 | Multiple congenital abnormalities in a newborn boy associated with maternal use of fluphenazine enanthate and other drugs during pregnancy. ( Bury, RG; Donaldson, GL, 1982) |
| "An effective and safe treatment for nausea and vomiting of pregnancy (NVP) is lacking." | 7.30 | Acupuncture and Doxylamine-Pyridoxine for Nausea and Vomiting in Pregnancy : A Randomized, Controlled, 2 ( An, CM; Cao, YJ; Chen, XY; Cong, J; Cui, YM; Feng, YH; Gao, JS; Hu, YH; Li, J; Li, L; Liu, JP; Liu, L; Liu, YX; Liu, ZL; Liu, ZS; Lu, ZL; Ma, HL; Mol, BWJ; Ng, EHY; Painter, RC; Qi, X; Qin, HC; Wang, CC; Wang, Y; Wang, YX; Wu, Q; Wu, XK; Yan, Y; Yang, XM; Yu, L; Zhang, B; Zhou, LL, 2023) |
| "We report information about an unpublished 1970s study ("8-way" Bendectin Study) that aimed to evaluate the relative therapeutic efficacy of doxylamine, pyridoxine, and dicyclomine in the management of nausea and vomiting during pregnancy." | 5.24 | 8-Way Randomized Controlled Trial of Doxylamine, Pyridoxine and Dicyclomine for Nausea and Vomiting during Pregnancy: Restoration of Unpublished Information. ( Persaud, N; Zhang, R, 2017) |
| "Doxylamine succinate-pyridoxine hydrochloride delayed release combination is safe and well tolerated by pregnant women when used in the recommended dose of up to 4 tablets daily in treating nausea and vomiting of pregnancy." | 5.20 | Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial. ( Caritis, SN; Clark, S; Hankins, GD; Koren, G; Matok, I; Mattison, DR; Miodovnik, M; Umans, JG, 2015) |
| " The authors' objective is to identify the determinants of adherence to delayed-release doxylamine-pyridoxine (Diclectin) in patients with nausea and vomiting of pregnancy (NVP)." | 5.16 | Determinants of adherence to delayed-release doxylamine and pyridoxine in patients with nausea and vomiting of pregnancy. ( Caritis, S; Chiossi, G; Clark, S; Costantine, MM; Hankins, GD; Koren, G; Matok, I; Miodovnik, M; Umans, JG, 2012) |
| "To evaluate the effectiveness of Diclectin (doxylamine succinate 10 mg-pyridoxine hydrochloride 10 mg, delayed-release preparation) as compared with placebo for nausea and vomiting of pregnancy." | 5.14 | Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. ( Caritis, SN; Clark, S; Hankins, GD; Koren, G; Mattison, DR; Miodovnik, M; Umans, JG, 2010) |
| "A double-blind comparison was undertaken between Debendox with 10mg of extra pyridoxine and placebo with 10mg of pyridoxine, in 56 women suffering from nausea and/or vomiting during the first 10 weeks of pregnancy." | 5.04 | Treatment of pregnancy sickness. ( Wheatley, D, 1977) |
| "For mild symptoms of nausea and emesis of pregnancy, ginger, pyridoxine, antihistamines, and metoclopramide were associated with greater benefit than placebo." | 4.93 | Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy: A Systematic Review. ( Beyer, F; Bradley, J; Bryant, A; McParlin, C; Moloney, E; Muirhead, CR; Nelson-Piercy, C; Newbury-Birch, D; Norman, J; O'Donnell, A; Robson, SC; Shaw, C; Simpson, E; Swallow, B; Vale, L; Yates, L, 2016) |
| "Diclectin (pyridoxine 10 mg and doxylamine 10 mg) has traditionally been used to treat nausea and vomiting of pregnancy (NVP); however, this drug is unavailable in many countries." | 3.79 | Evaluation of the efficacy and safety of bi-daily combination therapy with pyridoxine and doxylamine for nausea and vomiting of pregnancy. ( Ashkenazi-Hoffnung, L; Klinger, G; Merlob, P; Stahl, B, 2013) |
| "Diclectin, composed of 10 mg doxylamine succinate (DOX) and 10 mg pyridoxine hydrochloride, is the drug combination of choice for the management of nausea and vomiting during pregnancy in Canada." | 3.77 | Systemic bioavailability and pharmacokinetics of the doxylamine-pyridoxine delayed-release combination (Diclectin). ( Garcia-Bournissen, F; Gill, SK; Koren, G, 2011) |
| "Women who called the Motherisk NVP helpline, and were taking only Diclectin (vitamin B6 10 mg and doxylamine 10 mg), were enrolled in the study and assessed for the severity of nausea and vomiting of pregnancy (NVP) with the Motherisk-PUQE (pregnancy-unique quantification of emesis and nausea) scoring system." | 3.72 | Diclectin therapy for nausea and vomiting of pregnancy: effects of optimal dosing. ( Boskovic, R; Einarson, A; Koren, G; Maltepe, C; Wolpin, J, 2003) |
| "A delayed-release combination of doxylamine-pyridoxine (D-P) (Diclectin) is the only approved antiemetic medication for use in pregnancy in Canada." | 3.71 | The safety of higher than standard dose of doxylamine-pyridoxine (Diclectin) for nausea and vomiting of pregnancy. ( Atanackovic, G; Koren, G; Moretti, ME; Navioz, Y, 2001) |
| " Whenever she decreases her prednisone dose, her nausea increases tremendously even though she is taking two tablets of doxylamine and pyridoxine combination (Diclectin) daily." | 3.70 | Managing women with nausea and vomiting of pregnancy. Canadian consensus. ( , 2000) |
| " Although no definitive causative factor has been identified in previously reported cases, the affection in our case is possibly related to Debendox (Bendectin) and nitrofurantoin taken in early pregnancy for nausea and renal tract infection, respectively." | 3.69 | Congenital symmetrical weakness of the upper limbs resembling brachial plexus palsy: a possible sequel of drug toxicity in first trimester of pregnancy? ( Dubowitz, V; Muntoni, F; Philpot, J; Skellett, S, 1995) |
| "The antinausea drug combination, doxylamine/dicyclomine/pyridoxine (Debendox or Bendectin [US] ), has been withdrawn from the market because of litigation based upon charges that it causes congenital limb defects." | 3.67 | The innocent bystander. Doxylamine/dicyclomine/pyridoxine and congenital limb defects. ( Elliott, J; Forrest, J; Kricker, A; McCredie, J, 1984) |
| " The pregnancy was complicated by chronic maternal schizophrenia, severe toxaemia and maternal use of fluphenazine enanthate, dicyclomine hydrochloride, doxylamine succinate, pyridoxine hydrochloride and other drugs." | 3.66 | Multiple congenital abnormalities in a newborn boy associated with maternal use of fluphenazine enanthate and other drugs during pregnancy. ( Bury, RG; Donaldson, GL, 1982) |
| "An effective and safe treatment for nausea and vomiting of pregnancy (NVP) is lacking." | 3.30 | Acupuncture and Doxylamine-Pyridoxine for Nausea and Vomiting in Pregnancy : A Randomized, Controlled, 2 ( An, CM; Cao, YJ; Chen, XY; Cong, J; Cui, YM; Feng, YH; Gao, JS; Hu, YH; Li, J; Li, L; Liu, JP; Liu, L; Liu, YX; Liu, ZL; Liu, ZS; Lu, ZL; Ma, HL; Mol, BWJ; Ng, EHY; Painter, RC; Qi, X; Qin, HC; Wang, CC; Wang, Y; Wang, YX; Wu, Q; Wu, XK; Yan, Y; Yang, XM; Yu, L; Zhang, B; Zhou, LL, 2023) |
| "Nausea and vomiting are common in early pregnancy." | 2.50 | The pharmacologic management of nausea and vomiting of pregnancy. ( Briggs, GG; Niebyl, JR, 2014) |
| "Phenothiazines should be reserved for treating persistent vomiting that threatens the maternal nutritional status." | 2.37 | Safety and efficacy of antiemetics used to treat nausea and vomiting in pregnancy. ( Leathem, AM, 1986) |
| "Two hundred cases of verified brain tumors occurring in patients under 15 years of age were studied in relation to possible etiologic, genetic, and environmental risk factors." | 1.28 | Potential risk factors for brain tumors in children. An analysis of 200 cases. ( Giuffrè, R; Liccardo, G; Pastore, FS; Spallone, A; Vagnozzi, R, 1990) |
| " No dose-response relationship was evident." | 1.27 | Inter-Regional Epidemiological Study of Childhood Cancer (IRESCC): childhood cancer and the consumption of debendox and related drugs in pregnancy. ( Birch, JM; Cartwright, RA; Hartley, AL; Hopton, PA; Johnston, HE; Mann, JR; McKinney, PA; Stiller, CA; Waterhouse, JA, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (42.59) | 18.7374 |
| 1990's | 4 (7.41) | 18.2507 |
| 2000's | 12 (22.22) | 29.6817 |
| 2010's | 13 (24.07) | 24.3611 |
| 2020's | 2 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Saz-Leal, P | 1 |
| Zamorano-Domínguez, L | 1 |
| Frías, J | 1 |
| Guerra, P | 1 |
| Saura-Valls, M | 1 |
| Roca-Juanes, R | 1 |
| Nebot-Troyano, J | 1 |
| García-Aguilar, E | 1 |
| Vilchez, T | 1 |
| Urso, K | 1 |
| Wu, XK | 1 |
| Gao, JS | 1 |
| Ma, HL | 1 |
| Wang, Y | 1 |
| Zhang, B | 1 |
| Liu, ZL | 1 |
| Li, J | 1 |
| Cong, J | 1 |
| Qin, HC | 1 |
| Yang, XM | 1 |
| Wu, Q | 1 |
| Chen, XY | 1 |
| Lu, ZL | 1 |
| Feng, YH | 1 |
| Qi, X | 1 |
| Wang, YX | 1 |
| Yu, L | 1 |
| Cui, YM | 1 |
| An, CM | 1 |
| Zhou, LL | 1 |
| Hu, YH | 1 |
| Li, L | 1 |
| Cao, YJ | 1 |
| Yan, Y | 1 |
| Liu, L | 1 |
| Liu, YX | 1 |
| Liu, ZS | 1 |
| Painter, RC | 1 |
| Ng, EHY | 1 |
| Liu, JP | 1 |
| Mol, BWJ | 1 |
| Wang, CC | 1 |
| Ashkenazi-Hoffnung, L | 1 |
| Merlob, P | 1 |
| Stahl, B | 1 |
| Klinger, G | 1 |
| Niebyl, JR | 2 |
| Briggs, GG | 1 |
| Madjunkova, S | 1 |
| Maltepe, C | 3 |
| Koren, G | 12 |
| Clark, S | 3 |
| Hankins, GD | 3 |
| Caritis, SN | 2 |
| Umans, JG | 3 |
| Miodovnik, M | 3 |
| Mattison, DR | 2 |
| Matok, I | 2 |
| McParlin, C | 1 |
| O'Donnell, A | 1 |
| Robson, SC | 1 |
| Beyer, F | 1 |
| Moloney, E | 1 |
| Bryant, A | 1 |
| Bradley, J | 1 |
| Muirhead, CR | 1 |
| Nelson-Piercy, C | 1 |
| Newbury-Birch, D | 1 |
| Norman, J | 1 |
| Shaw, C | 1 |
| Simpson, E | 1 |
| Swallow, B | 1 |
| Yates, L | 1 |
| Vale, L | 1 |
| Zhang, R | 1 |
| Persaud, N | 1 |
| Nulman, I | 1 |
| Rovet, J | 1 |
| Barrera, M | 1 |
| Knittel-Keren, D | 1 |
| Feldman, BM | 1 |
| Gill, SK | 1 |
| Garcia-Bournissen, F | 2 |
| Tan, PC | 1 |
| Omar, SZ | 1 |
| Costantine, MM | 1 |
| Chiossi, G | 1 |
| Caritis, S | 1 |
| Brent, R | 2 |
| Kutcher, JS | 1 |
| Engle, A | 1 |
| Firth, J | 1 |
| Lamm, SH | 1 |
| Quinla, JD | 1 |
| Hill, DA | 1 |
| NULSEN, RO | 1 |
| GEIGER, CJ | 1 |
| FAHRENBACH, DM | 1 |
| HEALEY, FJ | 1 |
| Boskovic, R | 1 |
| Einarson, A | 1 |
| Wolpin, J | 1 |
| Thukral, C | 1 |
| Wolf, JL | 1 |
| Staroselsky, A | 1 |
| Aselton, P | 1 |
| Jick, H | 1 |
| Chentow, SJ | 1 |
| Perera, DR | 1 |
| Hunter, JR | 1 |
| Rothman, KJ | 1 |
| Hays, DP | 1 |
| McCredie, J | 1 |
| Kricker, A | 1 |
| Elliott, J | 1 |
| Forrest, J | 1 |
| Davis, JM | 1 |
| Huff, PS | 1 |
| Smith, RJ | 1 |
| David, TJ | 1 |
| Donaldson, GL | 1 |
| Bury, RG | 1 |
| Harron, DW | 1 |
| Griffiths, K | 1 |
| Shanks, RG | 1 |
| Philpot, J | 1 |
| Muntoni, F | 1 |
| Skellett, S | 1 |
| Dubowitz, V | 1 |
| Pastuszak, A | 1 |
| Ito, S | 1 |
| Mazzotta, P | 2 |
| Navioz, Y | 2 |
| Magee, LA | 2 |
| Bishai, R | 1 |
| Atanackovic, G | 2 |
| Levichek, Z | 1 |
| Pole, M | 1 |
| Moretti, ME | 1 |
| Wheatley, D | 1 |
| Smithells, RW | 1 |
| Sheppard, S | 1 |
| Giuffrè, R | 1 |
| Liccardo, G | 1 |
| Pastore, FS | 1 |
| Spallone, A | 1 |
| Vagnozzi, R | 1 |
| Skolnick, A | 1 |
| Leathem, AM | 1 |
| Jick, SS | 1 |
| Garrison, JM | 1 |
| Jedd, MB | 1 |
| Melton, LJ | 1 |
| Griffin, MR | 1 |
| Kaufman, B | 1 |
| Hoffman, AD | 1 |
| Broughton, D | 1 |
| O'Brien, PC | 1 |
| Walters, WA | 1 |
| Elbourne, D | 1 |
| Mutch, L | 1 |
| Dauncey, M | 1 |
| Campbell, H | 1 |
| Samphier, M | 1 |
| McKinney, PA | 1 |
| Cartwright, RA | 1 |
| Stiller, CA | 1 |
| Hopton, PA | 1 |
| Mann, JR | 1 |
| Birch, JM | 1 |
| Hartley, AL | 1 |
| Waterhouse, JA | 1 |
| Johnston, HE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevalence and Burden of Nausea and Vomiting in Pregnant Women in Switzerland: Survey Purity 2022[NCT06055192] | 200 participants (Anticipated) | Observational | 2023-09-30 | Not yet recruiting | |||
| A Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Of The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy[NCT00614445] | Phase 3 | 280 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| The Effect of Adjuvant Hypnosis Added to Conventional Therapy on Nausea and Vomiting in Hyperemesis Gravidarum: A Prospective Randomized Study[NCT04828967] | 41 participants (Actual) | Interventional | 2017-01-01 | Completed | |||
| Is the Application of Scopolamine Patch With or Without Intra-operative Acupressure Point P6 Stimulation More Effective Than Intra-operative Acupressure Point P6 Stimulation Alone?[NCT02960113] | Phase 4 | 240 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The objective of this double-blind, randomized, placebo-controlled study was to assess the efficacy, safety, and tolerability of oral Diclectin® in the treatment of nausea and vomiting of pregnancy (NVP) as measured by the Pregnancy Unique-Quantification of Emesis (PUQE) overall score of symptoms from baseline (Day 1) to end of study visit (Day 15). The PUQE score measured hours of nausea, number of times vomiting, and number of times retching for a TOTAL overall score of symptoms on a scale rated from 3 (no symptoms) to 15 (most severe). (NCT00614445)
Timeframe: Baseline (Day 1) to End of Study Visit Day 15 (± 1 day)
| Intervention | PUQE Score (Mean) |
|---|---|
| Diclectin® | -4.8 |
| Placebo | -3.9 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) after eversion of the uterus. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02960113)
Timeframe: After eversion of the uterus until replacement of the uterus
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 1.28 |
| Acupressure Point P6 | 1.09 |
| Scopolamine Patch + Acupressure Point P6 | 1.40 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) after replacement of the uterus. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02960113)
Timeframe: After replacement of the uterus and to the next 15 minutes
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 2.19 |
| Acupressure Point P6 | 2.19 |
| Scopolamine Patch + Acupressure Point P6 | 2.51 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) after the administration of the regional anesthesia medications. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02960113)
Timeframe: From administration of anaesthesia until eversion of uterus
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 2.71 |
| Acupressure Point P6 | 2.57 |
| Scopolamine Patch + Acupressure Point P6 | 2.84 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) upon arrival to the post-operative recovery room. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02960113)
Timeframe: 15 minutes after replacement of the uterus to arrival at post-anaesthesia care unit
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 0.18 |
| Acupressure Point P6 | 0.25 |
| Scopolamine Patch + Acupressure Point P6 | 0.23 |
The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea at any point during the surgical procedure in each group. (NCT02960113)
Timeframe: Throughout the entire surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 40 |
| Acupressure Point P6 | 39 |
| Scopolamine Patch + Acupressure Point P6 | 46 |
The investigators will perform objective assessments of whether or not the patients have vomited during the procedure. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: Throughout the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 24 |
| Acupressure Point P6 | 25 |
| Scopolamine Patch + Acupressure Point P6 | 31 |
Objective assessments of whether or not the patients have vomited at this point in the surgical procedure will be done. The investigators will analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: After eversion of to replacement of the uterus
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 8 |
| Acupressure Point P6 | 6 |
| Scopolamine Patch + Acupressure Point P6 | 9 |
Objective assessments of whether or not the patients have vomited at this point in the surgical procedure will be done. The investigators will analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: After replacement of the uterus and for next 15 minutes
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 10 |
| Acupressure Point P6 | 15 |
| Scopolamine Patch + Acupressure Point P6 | 12 |
Objective assessments of whether or not the patients have vomited at this point in the surgical procedure will be done. The investigators will analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: After the administration of the regional anesthesia medications until eversion of the uterus
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 20 |
| Acupressure Point P6 | 15 |
| Scopolamine Patch + Acupressure Point P6 | 20 |
Objective assessments of whether or not the patients have vomited at this point in the surgical procedure will be done. The investigators will analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: From 15 minutes after replacement of the uterus until arrival at the post-anaesthesia care unit
| Intervention | Participants (Count of Participants) |
|---|---|
| Scopolamine Patch | 1 |
| Acupressure Point P6 | 1 |
| Scopolamine Patch + Acupressure Point P6 | 4 |
Patients are asked their nausea and vomiting treatment satisfaction (0 = Not Satisfied, 10 = Extremely Satisfied). Patients are also asked their overall satisfaction with the procedure (0 = Not Satisfied, 10 = Extremely Satisfied). (NCT02960113)
Timeframe: Throughout the surgical procedure
| Intervention | units on a scale (Mean) |
|---|---|
| Scopolamine Patch | 9.29 |
| Acupressure Point P6 | 8.96 |
| Scopolamine Patch + Acupressure Point P6 | 9.59 |
13 reviews available for doxylamine and Complications, Pregnancy
| Article | Year |
|---|---|
Doxylamine/pyridoxine for nausea and vomiting in pregnancy.
Topics: Antiemetics; Dicyclomine; Doxylamine; Drug Combinations; Female; Humans; Nausea; Practice Guidelines | 2019 |
The pharmacologic management of nausea and vomiting of pregnancy.
Topics: Antiemetics; Dicyclomine; Doxylamine; Drug Combinations; Female; Histamine H1 Antagonists; Humans; N | 2014 |
The delayed-release combination of doxylamine and pyridoxine (Diclegis®/Diclectin ®) for the treatment of nausea and vomiting of pregnancy.
Topics: Antiemetics; Delayed-Action Preparations; Dicyclomine; Doxylamine; Drug Combinations; Female; Humans | 2014 |
Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy: A Systematic Review.
Topics: Acupuncture; Adrenal Cortex Hormones; Antiemetics; Doxylamine; Female; Histamine Antagonists; Humans | 2016 |
Clinical practice. Nausea and vomiting in pregnancy.
Topics: Adult; Chorionic Gonadotropin; Complementary Therapies; Diagnosis, Differential; Dicyclomine; Doxyla | 2010 |
Contemporary approaches to hyperemesis during pregnancy.
Topics: Adrenal Cortex Hormones; Antiemetics; Diet; Doxylamine; Female; Humans; Hyperemesis Gravidarum; Obst | 2011 |
Nausea and vomiting of pregnancy.
Topics: Acupressure; Antiemetics; Diagnosis, Differential; Doxylamine; Female; Humans; Hyperemesis Gravidaru | 2003 |
Therapy insight: drugs for gastrointestinal disorders in pregnant women.
Topics: Antiemetics; Constipation; Diarrhea; Doxylamine; Female; Gastroesophageal Reflux; Gastrointestinal D | 2006 |
Safety of drug therapy for nausea and vomiting of pregnancy.
Topics: Abnormalities, Drug-Induced; Antiemetics; Child; Dicyclomine; Doxylamine; Drug Combinations; Female; | 1980 |
Drugs in pregnancy.
Topics: Abnormalities, Drug-Induced; Animals; Counseling; Dicyclomine; Doxylamine; Drug Combinations; Drug E | 1998 |
Critical appraisal of drug therapy for nausea and vomiting of pregnancy: II. Efficacy and safety of diclectin (doxylamine-B6).
Topics: Antiemetics; Doxylamine; Female; Humans; Nausea; Pregnancy; Pregnancy Complications; Pyridoxine; Ran | 2000 |
Medical, social, and legal implications of treating nausea and vomiting of pregnancy.
Topics: Abnormalities, Drug-Induced; Antiemetics; Dicyclomine; Doxylamine; Drug Combinations; Female; Humans | 2002 |
Safety and efficacy of antiemetics used to treat nausea and vomiting in pregnancy.
Topics: Antiemetics; Antipsychotic Agents; Dicyclomine; Diphenhydramine; Doxylamine; Drug Combinations; Fema | 1986 |
7 trials available for doxylamine and Complications, Pregnancy
| Article | Year |
|---|---|
Acupuncture and Doxylamine-Pyridoxine for Nausea and Vomiting in Pregnancy : A Randomized, Controlled, 2
Topics: Acupuncture Therapy; Antiemetics; Child; Doxylamine; Female; Humans; Nausea; Pregnancy; Pregnancy Co | 2023 |
Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial.
Topics: Adult; Antiemetics; Delayed-Action Preparations; Dicyclomine; Double-Blind Method; Doxylamine; Drug | 2015 |
8-Way Randomized Controlled Trial of Doxylamine, Pyridoxine and Dicyclomine for Nausea and Vomiting during Pregnancy: Restoration of Unpublished Information.
Topics: Cooperative Behavior; Dicyclomine; Doxylamine; Drug Combinations; Female; Humans; Nausea; Physicians | 2017 |
Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial.
Topics: Adult; Delayed-Action Preparations; Dicyclomine; Dose-Response Relationship, Drug; Double-Blind Meth | 2010 |
Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial.
Topics: Adult; Delayed-Action Preparations; Dicyclomine; Dose-Response Relationship, Drug; Double-Blind Meth | 2010 |
Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial.
Topics: Adult; Delayed-Action Preparations; Dicyclomine; Dose-Response Relationship, Drug; Double-Blind Meth | 2010 |
Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial.
Topics: Adult; Delayed-Action Preparations; Dicyclomine; Dose-Response Relationship, Drug; Double-Blind Meth | 2010 |
Determinants of adherence to delayed-release doxylamine and pyridoxine in patients with nausea and vomiting of pregnancy.
Topics: Adult; Antiemetics; Cohort Studies; Delayed-Action Preparations; Dicyclomine; Double-Blind Method; D | 2012 |
Studies support Bendectin safety claim.
Topics: Antiemetics; Clinical Trials as Topic; Dicyclomine; Doxylamine; Drug Combinations; Female; Humans; I | 1981 |
Treatment of pregnancy sickness.
Topics: Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Dicyclomine; Double-Blind Method; Doxylamine; | 1977 |
34 other studies available for doxylamine and Complications, Pregnancy
| Article | Year |
|---|---|
Bioavailability of Cariban
Topics: Adult; Antiemetics; Biological Availability; Capsules; Delayed-Action Preparations; Doxylamine; Drug | 2023 |
Evaluation of the efficacy and safety of bi-daily combination therapy with pyridoxine and doxylamine for nausea and vomiting of pregnancy.
Topics: Administration, Oral; Adult; Antiemetics; Case-Control Studies; Dicyclomine; Dose-Response Relations | 2013 |
Diclegis for nausea and vomiting of pregnancy.
Topics: Antiemetics; Delayed-Action Preparations; Dicyclomine; Doxylamine; Drug Combinations; Female; Humans | 2013 |
Long-term neurodevelopment of children exposed to maternal nausea and vomiting of pregnancy and diclectin.
Topics: Adult; Antiemetics; Child; Child Development; Child, Preschool; Cohort Studies; Dicyclomine; Doxylam | 2009 |
Systemic bioavailability and pharmacokinetics of the doxylamine-pyridoxine delayed-release combination (Diclectin).
Topics: Adult; Antiemetics; Biological Availability; Canada; Delayed-Action Preparations; Dicyclomine; Doxyl | 2011 |
Bendectin and birth defects: hopefully, the final chapter.
Topics: Abnormalities, Drug-Induced; Adult; Adverse Drug Reaction Reporting Systems; Animals; Antiemetics; C | 2003 |
Bendectin and birth defects. II: Ecological analyses.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Adverse Drug Reaction Reporting Systems | 2003 |
Bendectin in the treatment of nausea of pregnancy.
Topics: Dicyclomine; Doxylamine; Drug Combinations; Histamine H1 Antagonists; Muscle Relaxants, Central; Nau | 1957 |
Bendectin in the treatment of nausea and vomiting in pregnancy.
Topics: Dicyclomine; Doxylamine; Drug Combinations; Histamine H1 Antagonists; Muscle Relaxants, Central; Nau | 1959 |
Diclectin therapy for nausea and vomiting of pregnancy: effects of optimal dosing.
Topics: Adult; Antiemetics; Dose-Response Relationship, Drug; Doxylamine; Drug Combinations; Female; Humans; | 2003 |
American Gastroenterological Association institute medical position statement on the use of gastrointestinal medication in pregnancy.
Topics: Antiemetics; Dicyclomine; Doxylamine; Drug Combinations; Female; Gastrointestinal Agents; Gastrointe | 2007 |
Pyloric stenosis and maternal Bendectin exposure.
Topics: Adult; Dicyclomine; Doxylamine; Drug Combinations; Drug Prescriptions; Female; Follow-Up Studies; Hu | 1984 |
Debendox and pregnancy.
Topics: Abnormalities, Drug-Induced; Dicyclomine; Doxylamine; Drug Combinations; Female; Humans; Nausea; Pre | 1984 |
Nausea and vomiting of pregnancy.
Topics: Antiemetics; Dicyclomine; Doxylamine; Drug Combinations; Female; Humans; Nausea; Pregnancy; Pregnanc | 1983 |
Bendectin: a case of mourning sickness.
Topics: Antiemetics; Dicyclomine; Doxylamine; Drug Combinations; Female; Humans; Nausea; Pregnancy; Pregnanc | 1983 |
The innocent bystander. Doxylamine/dicyclomine/pyridoxine and congenital limb defects.
Topics: Abnormalities, Drug-Induced; Antiemetics; Dicyclomine; Dose-Response Relationship, Drug; Doxylamine; | 1984 |
Good-bye, Bendectin, old friend.
Topics: Abnormalities, Drug-Induced; Dicyclomine; Doxylamine; Drug Combinations; Drug Industry; Female; Huma | 1984 |
Debendox does not cause the Poland anomaly.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Antiemetics; Dicyclomine; Doxylamine; Drug Com | 1982 |
Multiple congenital abnormalities in a newborn boy associated with maternal use of fluphenazine enanthate and other drugs during pregnancy.
Topics: Abnormalities, Drug-Induced; Cleft Lip; Cleft Palate; Dicyclomine; Doxylamine; Female; Fluphenazine; | 1982 |
Indications for bendectin narrowed.
Topics: Antiemetics; Carcinogens; Dicyclomine; Doxylamine; Drug Combinations; Female; Humans; Pregnancy; Pre | 1981 |
Debendox and congenital malformations in Northern Ireland.
Topics: Abnormalities, Drug-Induced; Antiemetics; Cyclohexanecarboxylic Acids; Dicyclomine; Doxylamine; Drug | 1980 |
Congenital symmetrical weakness of the upper limbs resembling brachial plexus palsy: a possible sequel of drug toxicity in first trimester of pregnancy?
Topics: Age of Onset; Antiemetics; Arm; Dermatoglyphics; Diagnosis, Differential; Dicyclomine; Doxylamine; D | 1995 |
Managing women with nausea and vomiting of pregnancy. Canadian consensus.
Topics: Adult; Anti-Inflammatory Agents; Antiemetics; Asthma; Diagnosis, Differential; Doxylamine; Drug Ther | 2000 |
Attitudes, management and consequences of nausea and vomiting of pregnancy in the United States and Canada.
Topics: Adult; Antiemetics; Attitude; Attitude of Health Personnel; Canada; Cost of Illness; Dicyclomine; Di | 2000 |
The safety of higher than standard dose of doxylamine-pyridoxine (Diclectin) for nausea and vomiting of pregnancy.
Topics: Antiemetics; Doxylamine; Drug Combinations; Female; Humans; Infant, Newborn; Nausea; Pregnancy; Preg | 2001 |
Teratogenicity testing in humans: a method demonstrating safety of bendectin.
Topics: Abnormalities, Drug-Induced; Animals; Antiemetics; Cyclohexanecarboxylic Acids; Dicyclomine; Doxylam | 1978 |
Congenital deformities associated with Bendectin.
Topics: Abnormalities, Drug-Induced; Adult; Cleft Lip; Cleft Palate; Cyclohexanecarboxylic Acids; Dicyclomin | 1977 |
Potential risk factors for brain tumors in children. An analysis of 200 cases.
Topics: Adolescent; Brain Neoplasms; Child; Dicyclomine; Doxylamine; Drug Combinations; Female; Glioma; Huma | 1990 |
Key witness against morning sickness drug faces scientific fraud charges.
Topics: Animals; Antiemetics; Australia; Biomedical Research; Dicyclomine; Doxylamine; Drug Combinations; Fe | 1990 |
Discontinuation of Bendectin.
Topics: Adult; Antiemetics; Dicyclomine; Doxylamine; Drug Combinations; Female; Humans; Nausea; Pregnancy; P | 1988 |
Factors associated with infantile hypertrophic pyloric stenosis.
Topics: Birth Order; Breast Feeding; Dicyclomine; Doxylamine; Drug Combinations; Female; Humans; Hypertrophy | 1988 |
The management of nausea and vomiting during pregnancy.
Topics: Antiemetics; Dicyclomine; Doxylamine; Drug Combinations; Female; Humans; Legislation, Drug; Nausea; | 1987 |
Debendox revisited.
Topics: Abnormalities, Drug-Induced; Antiemetics; Cleft Lip; Cleft Palate; Dicyclomine; Doxylamine; Drug Com | 1985 |
Inter-Regional Epidemiological Study of Childhood Cancer (IRESCC): childhood cancer and the consumption of debendox and related drugs in pregnancy.
Topics: Adolescent; Antiemetics; Child; Cyclohexanecarboxylic Acids; Dicyclomine; Dose-Response Relationship | 1985 |